[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,846,620
  • Shares Outstanding, K 100,550
  • Annual Sales, $ 2,861 M
  • Annual Income, $ 478,600 K
  • EBIT $ 789 M
  • EBITDA $ 806 M
  • 60-Month Beta 0.39
  • Price/Sales 6.12
  • Price/Cash Flow 34.73
  • Price/Book 5.14

Options Overview Details

View History
  • Implied Volatility 39.83% (+0.87%)
  • Historical Volatility 32.08%
  • IV Percentile 76%
  • IV Rank 60.40%
  • IV High 51.29% on 04/16/26
  • IV Low 22.35% on 08/29/25
  • Expected Move (DTE 9) 1.83 (1.03%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 212
  • Volume Avg (30-Day) 190
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 12,032
  • Open Int (30-Day) 12,132
  • Expected Range 176.41 to 180.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.85
  • Number of Estimates 7
  • High Estimate $2.64
  • Low Estimate $1.47
  • Prior Year $1.06
  • Growth Rate Est. (year over year) +74.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
155.30 +14.77%
on 06/16/26
178.75 -0.29%
on 07/07/26
+15.12 (+9.27%)
since 06/08/26
3-Month
125.64 +41.87%
on 04/13/26
178.75 -0.29%
on 07/07/26
+45.09 (+33.86%)
since 04/08/26
52-Week
122.14 +45.93%
on 02/12/26
178.75 -0.29%
on 07/07/26
+49.50 (+38.45%)
since 07/08/25

Most Recent Stories

More News
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

SAN DIEGO , July 1, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont...

NBIX : 178.24 (+0.42%)
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period

SAN DIEGO , June 15, 2026 /PRNewswire/ -- Soleno Therapeutics , a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment...

NBIX : 178.24 (+0.42%)
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

SAN DIEGO , June 15, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced clinical findings from the first retrospective case series in pediatric and adult patients...

NBIX : 178.24 (+0.42%)
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026

SAN DIEGO , June 15, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new two-year data from the Phase 3 CAHtalyst ® Pediatric study showing positive growth...

NBIX : 178.24 (+0.42%)
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients

SAN DIEGO , June 8, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new post-hoc data from the KINECT ® 4 clinical trial demonstrating that adults with...

NBIX : 178.24 (+0.42%)
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities

SAN DIEGO , June 8, 2026 /PRNewswire/ --  Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced new clinician-reported data in patients with intellectual and developmental disabilities...

NBIX : 178.24 (+0.42%)
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

SAN DIEGO , June 3, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present multiple new analyses of key clinical and patient-reported outcomes up to...

NBIX : 178.24 (+0.42%)
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

SAN DIEGO , May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:

NBIX : 178.24 (+0.42%)
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

SAN DIEGO , May 18, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced the presentation of new data from a clinician survey highlighting the functional impact...

NBIX : 178.24 (+0.42%)
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

SAN DIEGO , May 18, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the company's...

NBIX : 178.24 (+0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 182.82
2nd Resistance Point 180.72
1st Resistance Point 179.48
Last Price 178.24
1st Support Level 176.14
2nd Support Level 174.04
3rd Support Level 172.80

See More

52-Week High 178.75
Last Price 178.24
Fibonacci 61.8% 157.12
Fibonacci 50% 150.44
Fibonacci 38.2% 143.76
52-Week Low 122.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.